The Psychedelic Renaissance Needs a Recovery Protocol.
Therapeutic psychedelic use is exploding. MDMA-assisted therapy for PTSD. Psilocybin for treatment-resistant depression. Ketamine infusions for chronic pain and mood disorders. The clinical evidence is compelling, and millions of men are exploring these compounds under medical supervision or in decriminalized contexts.
What nobody discusses is the neurochemical recovery period. Psychedelics create profound perturbations in serotonergic, dopaminergic, and glutamatergic systems. These perturbations are therapeutically useful—they create the neuroplastic window where psychological change occurs. But the brain needs support during the rebalancing period that follows.
This is not about recreational drug use. This is about the biological recovery phase after a legitimate therapeutic intervention.
BPC-157: Serotonin System Modulation.
BPC-157 research demonstrates direct interactions with the serotonergic system. Published studies show it counteracts serotonin syndrome (a dangerous condition of serotonin excess), modulates 5-HT receptor activity, and normalizes serotonin metabolism after pharmacological perturbation.
MDMA releases massive amounts of serotonin (and dopamine) during the therapeutic session. The subsequent serotonin depletion creates the "Tuesday blues"—a period of low mood, fatigue, and emotional vulnerability 2-5 days after the session. BPC-157's serotonin-normalizing properties may support faster rebalancing during this window.
Psilocybin acts primarily through 5-HT2A receptor agonism. The integration period involves 5-HT2A receptor downregulation and neuroplastic consolidation. BPC-157's serotonergic modulation may support this recalibration.
Dosing: 250-500 mcg subcutaneous daily for 7-14 days following a therapeutic psychedelic session. Start the day after the session, not during.
Selank: Integration Anxiety.
The psychedelic integration period—the weeks following a therapeutic session where insights are consolidated into lasting change—is often accompanied by heightened emotional sensitivity and anxiety. This is therapeutically productive but can be destabilizing.
Selank modulates GABA and serotonin without sedation or dependence. For the integration period, it provides anxiolytic support that does not blunt the emotional processing that makes integration effective.
This is the critical distinction from benzodiazepines: benzos suppress the anxiety but also suppress the emotional processing. Selank reduces the anxiety while preserving the neuroplastic window. You stay emotionally open and cognitively clear.
Dosing: 250-500 mcg intranasal as needed during the integration period (typically 2-6 weeks post-session).
The Integration Support Protocol.
Post-session (days 1-3): BPC-157 250-500 mcg subcutaneous daily for serotonergic support. DSIP 100-250 mcg before bed for sleep architecture (psychedelics can disrupt sleep patterns for several days). Hydrate. Rest. Do not override the body's need for recovery.
Integration phase (weeks 1-6): BPC-157 250 mcg daily (maintenance). Selank 250 mcg intranasal as needed for anxiety management. Semax 200-400 mcg intranasal for cognitive clarity during psychological integration work.
Neuroplastic support: Semax upregulates BDNF, which supports the neuroplastic changes initiated by the psychedelic session. Using Semax during the integration period may extend and consolidate the neuroplastic window.
Gut support: Psychedelic sessions (particularly ayahuasca and psilocybin) can cause significant GI disturbance. Oral BPC-157 250 mcg addresses GI recovery alongside the neurological protocol.
This protocol is designed for supervised therapeutic use. If you are working with a therapist or clinician, discuss peptide use with them. Integration support is most effective when coordinated with professional guidance.
The Ethics and Boundaries.
This article exists because therapeutic psychedelic use is a legitimate and growing medical practice. It does not endorse recreational use, unsupervised experimentation, or any illegal activity.
Peptides are not psychedelic potentiators. They do not enhance the psychedelic experience. They support the neurobiological recovery and integration that follows. Timing them during a session is both unnecessary and inadvisable.
If you are considering therapeutic psychedelic use, do so through legal channels: FDA-approved ketamine clinics, state-licensed psilocybin service centers (Oregon, Colorado), or clinical trials. The therapeutic context provides medical oversight, psychological support, and safety infrastructure that self-directed use does not.
◆ Key Takeaway
BPC-157 modulates serotonin system recovery after psychedelic-induced perturbation. Selank provides anxiety support during integration without blunting emotional processing. Semax extends the neuroplastic window through BDNF upregulation. Dose post-session only (never during). This protocol supports the recovery phase of legitimate therapeutic use, not recreational experimentation.